Lantern Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lantern Pharma (LTRN).

Price Target Range — 1 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$25Upside to Avg. PT+3884.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 2, 2025	Lake Street	Chad Messer	Initiate	Buy	$25
Apr 25, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Neutral	—

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

Lake Street analyst Chad Messer initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

Benzinga Newsdesk

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08102023_LTRN_Vandermosten.pdf

Happy Mohamed

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King reiterates Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King maintains Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

Benzinga Newsdesk

Lantern Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Lantern Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

People Also Watch

People Also Watch

Lantern Pharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Lantern Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PROWatching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PROHC Wainwright & Co. Reiterates Neutral on Lantern Pharma

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

PROEF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PROEF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target